All In Biotech

Drug Trial Radar · NCT07220811

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Actual

Start

Dec 15, 2025

Primary completion

Mar 16, 2027

Study completion Dec 21, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks. Approximately 100 participants between the ages of 12 and 55 with documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut will be enrolled. In Part 1 (24 weeks), participants will be randomly assigned to receive RPT904 every 8 or 12 weeks (plus a loading dose at Week 2), or placebo. In Part 2 (24 weeks), participants who received RPT904 will continue on their assigned dosing schedule, and those who previously received placebo will be re-randomized to receive RPT904 either every 8 or 12 weeks (plus a loading dose at Week 26). All participants will attend study visits approximately every 2-6 weeks throughout both Part 1 and Part 2 to maintain blinding, regardless of treatment group or dosing frequency. The study is being conducted at multiple sites. The primary goal is to assess whether RPT904 helps participants tolerate higher amounts of a food allergen without dose-limiting allergic symptoms during a food challenge. The study will also monitor the safety and side effects of RPT904 over time. Each participant is expected to be in the study for about 68 to 74 weeks, including screening, treatment, and follow-up.

Conditions

  • Immune System Diseases
  • Ig-E Mediated Food Allergy

Interventions

  • RPT904Drug

    Subcutaneous injection once every 8 weeks

  • RPT904Drug

    Subcutaneous injection once every 12 weeks

  • PlaceboOther

    Subcutaneous injection at the intervening dosing visits

  • RPT904Drug

    Subcutaneous injection once every 8 weeks (Part 2)

  • RPT904Drug

    Subcutaneous injection once every 12 weeks (Part 2)

  • PlaceboOther

    Subcutaneous injection on schedules matching both the Q8W and Q12W arms (Part 1). Subcutaneous injection at the intervening dosing visits (Part 2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the ability to consume a food without dose-limiting symptoms during a DBPCFC at the end of Part 1 after treatment with either RPT904 or placeboTime frame: Approximately 24 weeks

Locations

37 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Palo Alto, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Ann Arbor, Michigan

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Great Neck, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Westmead, New South Wales, Australia

  • GSK Investigational Site

    South Brisbane, Queensland, Australia

  • GSK Investigational Site

    North Adelaide, South Australia, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Parkville, Victoria, Australia

  • GSK Investigational Site

    Parkville Melbourne, Victoria, Australia

  • GSK Investigational Site

    Murdoch, Western Australia, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Burlington, Ontario, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.